Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Back

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|November 17, 2010
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirDarren M Moss, Wai San Kwan, Neill J Liptrott, et al.
Chemical Research in Toxicology|March 2, 2013
Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patientsXiaoli Meng, Alice Howarth, Caroline J Earnshaw, et al.
AIDS (London, England)|May 24, 2013
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmentMohammed Lamorde, Pauline Byakika-Kibwika, Jonathan Mayito, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2018
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ARTOwain Roberts, Rajith K R Rajoli, David J Back, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2015
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adultsMohammed Lamorde, Stephen Walimbwa, Pauline Byakika-Kibwika, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2008
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavirMarco Siccardi, Antonio D'Avolio, Lorena Baietto, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentMarta Boffito, David J Back, Charles Flexner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence supportSaye H Khoo, Judith Lloyd, Mark Dalton, et al.
AIDS (London, England)|November 15, 2005
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRPOmar Janneh, Andrew Owen, Becky Chandler, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
Pharmacokinetics of saquinavir co-administered with cimetidineMarta Boffito, Pierluigi Carriero, Laura Trentini, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|November 17, 2010
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirDarren M Moss, Wai San Kwan, Neill J Liptrott, et al.
Chemical Research in Toxicology|March 2, 2013
Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patientsXiaoli Meng, Alice Howarth, Caroline J Earnshaw, et al.
AIDS (London, England)|May 24, 2013
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmentMohammed Lamorde, Pauline Byakika-Kibwika, Jonathan Mayito, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2018
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ARTOwain Roberts, Rajith K R Rajoli, David J Back, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2015
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adultsMohammed Lamorde, Stephen Walimbwa, Pauline Byakika-Kibwika, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2008
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavirMarco Siccardi, Antonio D'Avolio, Lorena Baietto, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentMarta Boffito, David J Back, Charles Flexner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence supportSaye H Khoo, Judith Lloyd, Mark Dalton, et al.
AIDS (London, England)|November 15, 2005
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRPOmar Janneh, Andrew Owen, Becky Chandler, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
Pharmacokinetics of saquinavir co-administered with cimetidineMarta Boffito, Pierluigi Carriero, Laura Trentini, et al.
Pageof 10